What medication options are appropriate for a patient with insomnia refractory to first‑line measures such as optimized sleep hygiene and cognitive‑behavioral therapy for insomnia?

Medication Options for Resistant Insomnia

For patients with insomnia refractory to CBT-I and sleep hygiene, eszopiclone, zolpidem, or suvorexant are the first-line pharmacologic options with the strongest evidence for efficacy, though effect sizes are small and treatment should be limited to short-term use (≤4 weeks) or as-needed dosing. 1, 2

Evidence-Based Medication Algorithm

First-Tier Pharmacologic Options (Strongest Evidence)

The American College of Physicians and American Academy of Sleep Medicine guidelines identify three agents with low-to-moderate strength evidence for improving both global and sleep-specific outcomes 1, 2:

• Z-drugs (Zolpidem, Eszopiclone): Effective for sleep initiation and maintenance with less deleterious effects than benzodiazepines when taken at appropriate dosing and timing 3. Safe in patients with depression or anxiety disorders but avoid in older adults due to cognitive impairment, falls, and fracture risk 4.

• Suvorexant (Orexin Receptor Antagonist): Can be used for periods up to 3 months or longer in select cases 5. Effective for both sleep initiation and maintenance in healthy individuals or those with mild cognitive impairment 4. Requires further study in patients with psychiatric and medical comorbidities 4.

Second-Tier Options (Lower Quality Evidence)

When first-tier agents are contraindicated or ineffective:

• Trazodone: Most commonly prescribed off-label treatment due to efficacy for both sleep initiation and maintenance and lack of abuse potential 4. Use at low doses (25-100mg). Evidence quality is lower than FDA-approved agents 1.

• Doxepin (low-dose): FDA-approved with evidence for short-term use (≤4 weeks) 2, 5. Can be considered when sedating properties are desired.

• Daridorexant (newer orexin antagonist): Recently approved with evidence for use up to 3 months 5. Place in therapy still being clarified 3.

Agents to AVOID

Strong recommendations against 5, 6:

• Benzodiazepines: Higher risk of cognitive impairment, falls, fractures, dementia, and major injury compared to alternatives 1. If used, limit to ≤4 weeks and avoid long-acting formulations 3.
• Antihistamines (diphenhydramine): Low efficacy, risk of next-day sedation and somnolence, particularly dangerous in older adults 3, 5.
• Antipsychotics: Not recommended for insomnia treatment 5, 6.
• Ramelteon/fast-release melatonin: Not recommended except prolonged-release melatonin in patients ≥55 years for up to 3 months 5.
• Phytotherapeutics (valerian): Not recommended 5, 6.

Critical Prescribing Principles

Duration and Dosing Strategy

• Prescribe at lowest effective dose for shortest duration 4
• As-needed dosing preferred over nightly use 4
• If nightly use required, limit to <6 weeks 4
• FDA documents advise dose reduction in women and older adults due to driving impairment and cognitive/behavioral changes 1

Patient-Specific Considerations

Older adults: Avoid Z-drugs and benzodiazepines due to falls, cognitive impairment, and fracture risk. Consider low-dose doxepin or prolonged-release melatonin (≥55 years) 4, 5.

Respiratory impairment: Avoid Z-drugs; consider orexin antagonists 4.

Cognitive impairment: Avoid Z-drugs and benzodiazepines; orexin antagonists may be appropriate for mild impairment 4.

Depression/anxiety: Z-drugs are safe and effective 4; trazodone provides dual benefit.

Substance use history: Avoid benzodiazepines and Z-drugs; prefer trazodone or orexin antagonists due to lower abuse potential 4.

Common Pitfalls

1. Long-term benzodiazepine use: Observational studies link chronic hypnotic use to increased dementia, fractures, and major injury 1. The 28-day prescription limit exists for good reason 3.

2. Polypharmacy without reassessment: Regularly evaluate whether medication can be tapered, especially when combined with CBT-I 7.

3. Ignoring medication timing: Z-drugs must be taken at the appropriate hour to maximize efficacy and minimize next-day effects 3.

4. Overlooking contraindications: Screen for sleep apnea, restless legs syndrome, and contributing medications before prescribing hypnotics 4.

Evidence Limitations

The comparative effectiveness and long-term efficacy of pharmacotherapies remain unknown 1. Most trials were small, short-term, and enrolled highly selected patients 1. Absolute effect sizes are small even for the best-studied agents 1. This underscores why pharmacotherapy should supplement, not replace, behavioral interventions when CBT-I has been inadequate.